These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 12020980)

  • 1. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
    Nerbrand C; Nyberg P; Nordström L; Samsioe G
    Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
    Sendag F; Karadadas N; Ozsener S; Bilgin O
    Arch Gynecol Obstet; 2002 Jan; 266(1):38-43. PubMed ID: 11998963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
    Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
    Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
    Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins.
    Marsh MS; Crook D; Whitcroft SI; Worthington M; Whitehead MI; Stevenson JC
    Obstet Gynecol; 1994 Jan; 83(1):19-23. PubMed ID: 8272301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women.
    Tonstad S; Ose L; Gørbitz C; Djøseland O; Bard JM; Fruchart JC
    J Intern Med; 1995 Jul; 238(1):39-47. PubMed ID: 7608645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
    Godsland IF
    Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
    Heikkinen AM; Niskanen L; Ryynänen M; Komulainen MH; Tuppurainen MT; Parviainen M; Saarikoski S
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):402-7. PubMed ID: 9974425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions.
    Farish E; Spowart K; Barnes JF; Fletcher CD; Calder A; Brown A; Hart DM
    Atherosclerosis; 1996 Sep; 126(1):77-84. PubMed ID: 8879436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy.
    Heikkinen AM; Tuppurainen MT; Niskanen L; Komulainen M; Penttilä I; Saarikoski S
    Eur J Endocrinol; 1997 Nov; 137(5):495-502. PubMed ID: 9405029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
    Perera M; Sattar N; Petrie JR; Hillier C; Small M; Connell JM; Lowe GD; Lumsden MA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.